The results of a randomized controlled trial demonstrate that the novel oral anticoagulant apixaban, administered up to 5 days before the start of chemotherapy, significantly reduces the risk of venous thromboembolism (VTE) in patients with intermediate-risk or high-risk cancers of various types, including lymphomas, gynaecological and pancreatic cancers. Patients were randomized 1:1 to receive either apixaban or placebo, followed by chemotherapy appropriate to their cancer type. A total of 12 patients (4.2%) in the apixaban group had VTEs, compared with 28 patients (10.2%) in the placebo group (HR 0.41; 95% CI 0.26– 0.65; P < 0.001). This reduction in VTE risk comes at the cost of an increased risk of major bleeding episodes: major bleeding occurred in 10 patients (3.5%) in the apixaban group versus 5 patients (1.8%) in the placebo group (HR 2.00; 95% CI 1.01– 3.95; P = 0.046). However, results of the competing-risk analysis favour the use of apixaban in this patient population (HR 0.42; 95% CI 0.27–0.65).
References
Original article
Carrier, M. et al. Apixaban to prevent venous thromboembolism in patients with cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1814468 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sidaway, P. Apixaban reduces risk of thromboembolism. Nat Rev Clin Oncol 16, 144 (2019). https://doi.org/10.1038/s41571-018-0162-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0162-4